Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RESTART

Financiado

Cerrado

Refined screening for novel targets in the tumor vasculature

Angiostatic compounds have made their way into the daily clinical management of cancer, but their impact on patient survival is rather limited. This is likely due to the fact that most current drugs are antagonists of tumor produc... ver más

28/02/2017

STICHTING VU

183K€

Presupuesto del proyecto: 183K€

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

STICHTING VU

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GENE Genomic screening of the Embryo for Novel targets in the tum... 176K€ Cerrado

TECNEC Preclinical concept validation of tumor endothelial cell met... 3M€ Cerrado

AngioResist Coordinated Development of Inhibitors and Biomarkers for Res... 150K€ Cerrado

ANGIO-IMAGE ANGIO tracer for immuno PET imaging a stratification and mo... 71K€ Cerrado

PREDICT THE DRUG Using ex vivo functional genomics as biomarker to predict th... 150K€ Cerrado

BIO2014-57291-R NUEVAS ESTRATEGIAS PARA EL DESCUBRIMIENTO DE DIANAS MOLECULA... 303K€ Cerrado

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 183K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Angiostatic compounds have made their way into the daily clinical management of cancer, but their impact on patient survival is rather limited. This is likely due to the fact that most current drugs are antagonists of tumor produced growth factors, a strategy expected to induce drug resistance. A better strategy would be to target the tumor vasculature directly. Several markers of tumor endothelial cells have been described but most of them lack sufficient specificity. The applicant proposes to use Next Generation Sequencing (NGS) to identify the population of genes specifically expressed in primary prostate carcinoma and its metastases. Subsequently, this population of genes is screened for genes that are re-used during angiogenesis, and consequently overexpressed in the tumor endothelium. Prioritization of targets will be done by (i) level of (over)expression, (ii) membrane expression or secretion and (iii) existence of human ortho/homologs. After initial validation by qPCR in the source transcriptomes used for NGS, further validation of the targets will be done through loss- and gain-of-function assays. For 2-3 targets monoclonal antibodies will be generated. These antibodies will be tested in in vitro angiogenesis bioassays, and applicability will be preliminary tested in a preclinical mouse tumor model. Finally, the human ortho/homologs of the gene will be identified and validated for overexpression in human tumors. The novelty of the proposed work is the NGS approach for selection of tumor endothelial markers, through screening for high expression in the full tumor transcriptome and absence in healthy full body RNA. The prior experience of the applicant and the host laboratory will help the current project to succeed in reaching its goals. In our view, it is feasible to develop a new vascular targeting strategy, ready for translation to clinical testing. The proposed work will strongly reinforce the collaboration between two European institutes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores